List view / Grid view
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
Researchers found that SARS-CoV-2 persists in the brain after it is cleared in the lungs and concluded the severest and longest lasting symptoms of COVID-19 may be caused by brain infection.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
